Mayo Clinic is researching advanced prostate cancer treatments through the PROMOTE study, focusing on genetic sequencing of tumors. This study targets castrate-resistant prostate cancer (CRPC), which no longer responds to standard hormone treatments. By analyzing genetic changes in metastatic tumors, researchers intend to tailor treatments to individual patients, even though a cure for CRPC remains elusive. Participants will undergo tumor biopsies and receive close monitoring to assess treatment response, highlighting the study's personalized approach in addressing this challenging cancer stage.
Researchers at Mayo Clinic are using genetic sequencing to improve treatments for men with advanced prostate cancer, particularly focusing on the challenges of castrate-resistant prostate cancer (CRPC).
The PROMOTE study aims to personalize treatment by analyzing genetic changes in metastatic tumors, helping to understand how individual tumors respond to therapies, thereby improving outcomes.
Despite available treatments for CRPC that can prolong life after hormone therapies, a definitive cure is absent, necessitating ongoing research and personalized medicine.
The study highlights the importance of understanding genetic information to predict how different patients will respond to various treatments for CRPC.
#prostate-cancer #hormone-therapy #genetic-sequencing #castrate-resistant-prostate-cancer #cancer-research
Collection
[
|
...
]